Washington Trust Advisors Inc. Reduces Stock Holdings in IQVIA Holdings Inc. $IQV

Key Points

• Washington Trust Advisors reduced its IQVIA stake by 6.1% in the second quarter, selling 7,828 shares and retaining 120,941 shares worth approximately $23.4 million. IQVIA remains the fund’s 13th-largest holding and represents about 1.7% of its portfolio.
• Analysts maintain a generally positive view, with IQVIA receiving a “Moderate Buy” consensus rating and an average price target of $243.62. However, insiders sold 15,581 shares worth roughly $3.8 million over the past three months.
• IQVIA reported quarterly earnings of $3.15 per share, beating estimates of $3.03, while revenue rose 8.7% year over year to $4.37 billion. Shares opened at $267.34, near the company’s 12-month high of $271.80.

Washington Trust Advisors Inc. reduced its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 6.1% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 120,941 shares of the medical research company's stock after selling 7,828 shares during the quarter. IQVIA comprises approximately 1.7% of Washington Trust Advisors Inc.'s investment portfolio, making the stock its 13th largest position. Washington Trust Advisors Inc. owned about 0.07% of IQVIA worth $23,368,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Apella Capital LLC raised its position in shares of IQVIA by 5.1% in the first quarter. Apella Capital LLC now owns 1,196 shares of the medical research company's stock valued at $211,000 after buying an additional 58 shares during the last quarter. Quadrant Capital Group LLC grew its stake in IQVIA by 1.3% during the 4th quarter. Quadrant Capital Group LLC now owns 4,792 shares of the medical research company's stock valued at $1,080,000 after acquiring an additional 60 shares in the last quarter. Private Advisor Group LLC raised its holdings in IQVIA by 1.0% in the 3rd quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company's stock valued at $1,163,000 after acquiring an additional 63 shares during the last quarter. Breakwater Capital Group lifted its stake in IQVIA by 3.2% in the 2nd quarter. Breakwater Capital Group now owns 2,073 shares of the medical research company's stock worth $401,000 after purchasing an additional 64 shares in the last quarter. Finally, First Growth Capital LLC boosted its holdings in shares of IQVIA by 3.2% during the 1st quarter. First Growth Capital LLC now owns 2,173 shares of the medical research company's stock worth $375,000 after purchasing an additional 68 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on IQV shares. Deutsche Bank Aktiengesellschaft set a $240.00 price target on IQVIA in a report on Thursday, July 9th. Stifel Nicolaus upped their target price on IQVIA from $220.00 to $276.00 and gave the company a "buy" rating in a report on Wednesday, July 29th. Robert W. Baird raised their target price on IQVIA from $252.00 to $287.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 29th. Barclays reissued an "overweight" rating on shares of IQVIA in a report on Tuesday, July 28th. Finally, Morgan Stanley reaffirmed an "equal weight" rating and set a $200.00 target price (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $243.62.

Insider Transactions at IQVIA

In related news, insider James G. Berkshire sold 2,668 shares of the business's stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total value of $697,228.44. Following the sale, the insider owned 10,890 shares in the company, valued at approximately $2,845,883.70. The trade was a 19.68% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Eric Sherbet sold 5,000 shares of the stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total value of $1,245,800.00. Following the transaction, the insider directly owned 20,999 shares in the company, valued at approximately $5,232,110.84. The trade was a 19.23% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 15,581 shares of company stock worth $3,796,021 in the last three months. Company insiders own 1.70% of the company's stock.

IQVIA Stock Down 0.2%

Shares of IQV opened at $267.34 on Monday. The company's 50-day moving average price is $230.54 and its 200 day moving average price is $192.84. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $271.80. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The firm has a market cap of $44.00 billion, a P/E ratio of 33.17, a price-to-earnings-growth ratio of 2.29 and a beta of 1.18.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts' consensus estimates of $3.03 by $0.12. The business had revenue of $4.37 billion during the quarter, compared to analysts' expectations of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business's revenue for the quarter was up 8.7% on a year-over-year basis. During the same period last year, the business earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, sell-side analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA Company Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source